Fludarabine induced Immune Thrombocytopenia in a patient with CD5 Positive B Cell Chronic Lymphocytic Leukemia

Journal of the Pakistan Medical Association

Volumn 53, Issue 10, 2003, Pages 496-497

  Usman, M ^a   Adil, S N ^a   Sajid, R ^a   Khurshid, M ^a  

^a AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD5 ANTIGEN; CHLORAMBUCIL; FLUDARABINE; IMMUNOGLOBULIN; PREDNISOLONE;

ADULT; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CASE REPORT; CHRONIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; EPISTAXIS; FEMALE; HEMOGLOBIN DETERMINATION; HEMOLYTIC ANEMIA; HUMAN; NEUROTOXICITY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; FEMALE; HUMANS; LEUKEMIA, B-CELL, CHRONIC; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; VIDARABINE;

EID: 0347985052     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Keating MJ, Kantarjian H, Talpaz M, et al. Fludarabine - a new agent with major activity against chronic lymphocytic leukemia. Blood 1989;74:19-25.
2. Martin S, Tallman DH. Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood 1995;7:2463-74.
3. Johnson S, Smith AG. Multicentre prospective randomized trial of Fludarabine versus Cyclophosphamide, Doxorubicin, and Prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukemia. Lancet 1996;347:1432-8.
4. Redman JR, Cabanillas F, Velasquez WAS, et al. Phase II trial of Fludarabine phosphate in lymphoma. An effective new agent in low-grade lymphoma. J Clin Oncol 1992;10:790.
5. Kantarjian HM, Alexanian R, Koller CA, et al. Fludarabine therapy in macroglobulinemia lymphoma. Blood 1990;75:1928.
6. Champlin R, Khouri I, Anderlini P, et al. Nonmyeloablative preparative regimens for allogenic hematopoietic transplantation. Bone Marrow Transplant 2001;27:S13-S22.
7. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995;13:2431-48.
8. Myint H, Copplestone JA. Fludarabine related autoimmune haemolytic anemia in patients with chronic lymphocytic leukemia. Br J Haematol 1995;91:341-4.
9. Leach M, Parsons RM, Reilly JT, et al. Autoimmune thrombocytopenia: a complication of fludarabine therapy in lymphoproliferative disorders. Clinical Lab Haematol 2000;3:175-8.
10. Hamblin TJ, Oscier DG, Young BJ. Autoimmunity in chronic lymphocytic leukemia. J Clin Pathol 1986;39:713-16.
11. Ulrich D, Wiprecht A. Spectrum and frequency of autoimmune derangements in lymphoproliferative disorders: analysis of 637 cases and comparison with myeloproliferative diseases. Br J Haematol 1987;67:235-9.
12. Lagneaux L, Delforge A. Heterogeneous response of B-lymphocytes to transforming growth factor-beta in B-cell chronic lymphocytic leukemia: correlation with the expression of TGF-beta receptor. Br J Haematol 1997;97:612.
13. Cantwell MJ, Hua T, Pappas J, et al. Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nature Med 1997;3:984.
14. Ranheim EA, Kipps TG. Activated t-cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 1993; 177 925.
15. Kipps TJ, Carson DA. Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood 1993;81:2475.